DaVita management check
DVA · Health Care · Health Care Services · CEO Javier J. Rodriguez
Filings as of
Closest peers in Health Care Services
- 60CICigna80
- 114ELVElevance Health75
- 126DVADaVita74
- 218DGXQuest Diagnostics67
- 223LHLabcorp66
- 305CVSCVS Health61
The seven checks
- WatchTrailed its chosen peers
Have owners done well?
What $100 became since fiscal 2021
3237thDetail
$100 invested at the start of fiscal 2021 grew to $97, against $113 for the peer group the company picked itself.
- GoodPay rose and fell with returns
Does pay follow performance?
Pay actually paid $100 value, each on its own scale
9271stDetail
Over 5 years, the CEO's pay actually paid (equity valued at the share price) had a correlation of 0.83 with shareholder return. 1 means pay moved in step; below 0, the opposite way.
- Watch1.7% of net income
What does the CEO cost owners?
$18.2m pay · $1.1bn net income, FY2025
3133rdDetail
$18.2m of reported pay in fiscal 2025, against $1.1bn of net income.
- WatchCEO stake ≈ 8.0 years of pay
Do they own the stock?
835,243 shares ≈ $145.8m
6 mo: ▲ $0 bought · ▼ $17.7m sold
6065thDetail
The CEO holds 835,243 shares, directly or through trusts (unvested awards not counted): about 8.0 years of pay. 2 insiders sold $17.7m in the last six months and none bought.
- GoodShare count shrinking
Are owners being diluted?
Diluted shares −9.8% a year; flagged above +2%
Stock pay 1.0% of revenue
100100thDetail
Diluted shares changed -9.8% a year over the last three fiscal years. Stock-based pay was 1.0% of revenue in the latest year.
- Good2 leadership filings in 3 years
Is leadership stable?
2 filings under 8-K 5.02 in 3 years
CEO: Javier J. Rodriguez
100100thDetail
CEO in the pay table: Javier J. Rodriguez. 2 filings under 8-K item 5.02 (officers or directors leaving or joining, or new pay arrangements) in the last 3 years.
- GoodNo red flags on file
Are the books clean?
Since 2021
- 0Restated
- 0Auditor changes
- 0Late filings
- 010-K amended
100100thDetail
No restatements, auditor changes or late filings since 2021.
Reading the scores
Each check scored 0–100 from its own figure. The tick is the Health Care median; the ordinal is the share of ranked S&P 500 companies it matches or beats.
Hover a chart for its figures. Detail has the full reading.
Pay versus performance
From the proxy statement filed April 22, 2026.
Pay tied most to Adjusted Earnings per Share
Other key measuresFree cash flowAdjusted operating incomeTotal shareholder return
Show the figures
| Fiscal year | CEO | CEO pay | Actually paid | Other executives (avg) | $100 became | Peers | Net income |
|---|---|---|---|---|---|---|---|
| 2025 | Javier J. Rodriguez | $18.2m | $18.9m | $4.4m | $97 | $113 | $1.1bn |
| 2024 | Javier J. Rodriguez | $21.8m | $20.6m | $5.3m | $127 | $95 | $1.3bn |
| 2023 | Javier J. Rodriguez | $6.7m | $4.8m | $6.4m | $89 | $93 | $957.0m |
| 2022 | Javier J. Rodriguez | $3.0m | −$86.4m | $4.2m | $64 | $88 | $781.6m |
| 2021 | Javier J. Rodriguez | $3.3m | −$13.1m | $4.3m | $97 | $110 | $1.2bn |
Insiders and the CEO's stakeSelling
- Chief Executive Officer
- Javier Rodriguez
- Shares held
- 835,243
- At that filing's price
- ≈ $145.8m
- Latest Form 4
- Nov 15, 2026
2 insiders sold $17.7m in the last six months and none bought.
Open-market trades by officers and directors since May 21, 2026.
- SoldJavier RodriguezChief Executive Officer$14.5mJun 16, 2026
- SoldKathleen Alyce WatersChief Legal & Pub. Affairs Off$3.2mJun 15, 2026
Leadership and governance on file
All 7 filings
- Sep 13, 2024Leadership change8-K 5.02
- Apr 10, 2024Leadership change8-K 5.02
- Jul 25, 2023Leadership change8-K 5.02
- Jul 13, 2023Leadership change8-K 5.02
- Mar 21, 2023Leadership change8-K 5.02
- Sep 13, 2022Leadership change8-K 5.02
- Apr 8, 2022Leadership change8-K 5.02
Latest shareholder vote results: Jun 8, 2026, including the say-on-pay vote.
Where the money went
2021–2025: $5.3bn returned to owners in buybacks and dividends, 101% of net income, and $552.8m of pay in stock.
Show the figures
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $11.6bn | $11.6bn | $12.1bn | $12.8bn | $13.6bn |
| Net income | $1.2bn | $781.6m | $957.0m | $1.3bn | $1.1bn |
| Stock-based pay | $102.2m | $95.4m | $112.4m | $102.8m | $140.0m |
| Buybacks | $1.5bn | $802.2m | $272.2m | $1.4bn | $1.3bn |
| Dividends | $0 | $0 | $0 | $0 | $0 |
| Diluted shares | 110m | 96m | 93m | 87m | 76m |
Educational only, not investment advice. Figures are as filed with the SEC: pay from the proxy's pay-versus-performance table, capital allocation from 10-K XBRL data, insider trades from Form 4s over the last six months, events from the last 5 years of filings. The peer group is the one the company chose. See the method.